Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28808541 | 0.89 | HDAC9 (0.33) | AKR1C1HDAC9 | |
| SCHEMBL29094947 | 0.83 | TSHR (0.39) | AKR1C1HDAC9LMNAHTTTSHR | |
| SCHEMBL1434701 | 0.78 | HDAC9 (0.34) | AKR1C1HDAC9HDAC4TSHRMAPK1 | |
| SCHEMBL28185148 | 0.78 | OPRM1 (0.34) | AKR1C1HDAC9HDAC4KMT2A | |
| SCHEMBL28794322 | 0.77 | HDAC9 (0.39) | AKR1C1HDAC9HDAC4TSHRMAPK1 | |
| SCHEMBL28468921 | 0.72 | AKR1C1 (0.36) | AKR1C1HDAC9LMNAHTTHDAC4 | |
| SCHEMBL27321836 | 0.71 | AKR1C1 (0.35) | AKR1C1HDAC9LMNAHTTHDAC4 | |
| Naphthalene SCHEMBL27264877 | 0.71 | KDM4E (0.33) | TSHRMAPK1HSD17B10TDP1KMT2A | |
| Biphenyl SCHEMBL28741663 | 0.71 | KMO (0.35) | LMNAMAPK1KMT2A | |
| SCHEMBL8210522 | 0.71 | TSHR (0.37) | TSHRMAPK1HSD17B10TDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120130071-A1 | METHOD FOR OXIDIZING METHANE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2012-05-24 | — | — | US | claimed |
| CN-114716592-B | Propylene polymerization catalyst component, catalyst and preparation method thereof | 中国石油天然气股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-114716592-A | Propylene polymerization catalyst component, catalyst and preparation method thereof | 中国石油天然气股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20120130071-A1 | METHOD FOR OXIDIZING METHANE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130071-A1 | METHOD FOR OXIDIZING METHANE | TST, MGMT, PMS2 | AKR1C1 3521/4885HDAC9 1780/4885LMNA 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.